, Singapore
725 views
Photo from Envato Elements

Singapore maintains tariffs on US goods in 2025: report

However, Singapore is vulnerable to a potential 25% US tariff on pharmaceuticals. 

Singapore’s tariffs on US goods—and vice versa—will remain unchanged in 2025, according to a report by Natixis CIB. This means Singapore will neither need to lower its tariffs on US goods nor face higher tariffs from the US.

However, Singapore remains among the most vulnerable to a potential 25% US tariff on pharmaceuticals. At the same time, it stands to benefit from the ongoing reshuffling of global supply chains.

According to Natixis CIB, if Trump moves forward with broader tariff measures, the rest of emerging Asia will be negatively impacted, particularly Vietnam, while China could gain a strategic advantage.

Meanwhile, India and Thailand currently have the highest reciprocal tariff differentials with the US.

Currently, only China is subject to Trump-era tariffs, with an additional 20% tariff on top of already high trade and investment barriers. Other Asian countries remain cautious as further trade measures may be introduced in the coming months.

Join Singapore Business Review community

Follow the link for more news on

Join Singapore Business Review community
A NOTE FROM SINGAPORE BUSINESS REVIEW

Reaching the people who run Asia's businesses is harder than it used to be.

Inboxes are crowded. Attention is short. The executives you most want to reach — the founders, CFOs, and operators who actually move budgets — are the hardest to find through the usual channels. If you're building a company, a category, or a reputation, you already know this.

We've spent twenty years building the room they read. Singapore Business Review is where senior decision makers in Singapore and across Southeast Asia come for business coverage they can't get elsewhere — in print, online, and in person at the summits and roundtables we host across seven markets.

If you have something these readers should know about — a point of view worth publishing, a product worth their attention, an event worth their time — we'd like to hear what you're trying to do.